About Keratin, type I cuticular Ha8
Keratin, type I cuticular Ha8 (KRT38) is a protein
from Homo sapiens identified by UniProt accession
O76015, 456 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Keratin, type I cuticular Ha8 |
| UniProt accession | O76015 |
| Gene | KRT38 |
| Organism | Homo sapiens |
| Length | 456 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (12)
Diseases linked to this target (Open Targets).
- head and neck squamous cell carcinoma · score 0.18
- glioblastoma multiforme · score 0.18
- prostate adenocarcinoma · score 0.18
- breast adenocarcinoma · score 0.18
- esophageal cancer · score 0.14
- neuroblastoma · score 0.13
- breast carcinoma · score 0.01
- urinary bladder carcinoma · score 0.01
- neoplasm · score 0.00
- metastatic neoplasm · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O76015-F1 | alphafold | PREDICTED | 74.14 | — |
Amino-acid sequence (456 residues)
MTSSYSSSSC PLGCTMAPGA RNVSVSPIDI GCQPGAEANI APMCLLANVA HANRVRVGST PLGRPSLCLP PTCHTACPLP GTCHIPGNIG ICGAYGENTL NGHEKETMQF LNDRLANYLE KVRQLEQENA ELEATLLERS KCHESTVCPD YQSYFHTIEE LQQKILCSKA ENARLIVQID NAKLAADDFR IKLESERSLR QLVEADKCGT QKLLDDATLA KADLEAQQES LKEEQLSLKS NHEQEVKILR SQLGEKLRIE LDIEPTIDLN RVLGEMRAQY EAMLETNRQD VEQWFQAQSE GISLQDMSCS EELQCCQSEI LELRCTVNAL EVERQAQHTL KDCLQNSLCE AEDRFGTELA QMQSLISNVE EQLSEIRADL ERQNQEYQVL LDVKTRLENE IATYRNLLES EDCKLPCNPC STSPSCVTAP CAPRPSCGPC TTCGPTCGAS TTGSRF
Explore Keratin, type I cuticular Ha8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets